medigraphic.com
Instituto Nacional de Salud Pública

2018, Número 6

<< Anterior Siguiente >>

salud publica mex 2018; 60 (6)


El efecto de un refuerzo de la vacuna tetravalente de VPH después de 51 meses: implicaciones para un esquema de vacunación extendido

Lazcano-Ponce E, Carnalla-Cortés M, Barrientos-Gutiérrez T, Torres-Ibarra L, Cruz-Valdez A, Salmerón J, Hernández-Avila M

Idioma: Ingles.
Referencias bibliográficas: 26
Paginas: 666-673
Archivo PDF: 540.08 Kb.


RESUMEN

Objetivo. Evaluar la no inferioridad entre dos diferentes esquemas de vacunación un mes después de la administración de la tercera dosis. Material y métodos. Se evaluaron los títulos de anticuerpos anti-VPH 16/18 inducidos por la vacuna contra VPH tetravalente administrada en niñas de 9 a 10 años utilizando dos esquemas diferentes: tradicional (0-2-6) y alternativo (0-6-50). Se recolectaron muestras en los meses 7, 21 y 51. Resultados. La media geométrica de títulos de anticuerpos un mes después de la aplicación de la tercera dosis –mes 51 para la alternativa y mes 7 para el tradicional– fueron 1.55 para HPV16 (95% IC 1.15-2.08) y 1.53 para HPV18 (95% IC 1.12-2.09). La tasa de seropositividad fue superior a 99% en ambos grupos. Conclusiones. la aplicación de un esquema alternativo de tres dosis (0-6-50 meses) en niñas parece inducir una respuesta inmune no inferior al esquema tradicional un mes después de la última dosis. Se necesitan más estudios para determinar las dosis mínimas e intervalos óptimos para obtener la mejor cobertura para la infección por VPH.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. World Health Organization [internet]. WHO; c2018- [cited 2018 Nov 8]. Director-General calls for all countries to take action to help end the suffering caused by cervical cancer; [about 2 screens]. Available from: https://www.who.int/reproductivehealth/call-to-action-eliminationcervical- cancer/en/

  2. Gómez-Dantés H, Lamadrid-Figueroa H, Cahuana-Hurtado L, Silverman- Retana O, Montero P, González-Robledo MC, et al. The burden of cancer in Mexico, 1990-2013. Salud Publica Mex. 2016;58(2):118-31. https://doi. org/10.21149/spm.v58i2.7780

  3. Bray F, Piñeros M. Cancer patterns, trends and projections in Latin America and the Caribbean: A global context. Salud Publica Mex. 2016;58(2):104-17. https://doi.org/10.21149/spm.v58i2.7779

  4. Brandon D, Kimmel M, Kuriyakose SO, Kostanyan L, Mesaros N. Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults. Vaccine. 2018;36:6325-33. https://doi.org/10.1016/j.vaccine.2018.08.051

  5. Kadlecek V, Borja-Tabora CF, Eder-Lingelbach S, Gatchalian S, Kiermayr S, Sablan B Jr, et al. Antibody persistence up to 3 years after primary immunization with inactivated Japanese encephalitis vaccine IXIARO in Philippine children and effect of a booster dose. Pediatr Infect Dis J. 2018;37(9):e233-40. https://doi.org/10.1097/INF.0000000000002124

  6. Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4(7):e453- 63. https://doi.org/10.1016/S2214-109X(16)30099-7

  7. Gilca V, Salmerón-Castro J, Sauvageau C, Ogilvie G, Landry M, Naus M, et al. Early use of the HPV 2-dose vaccination schedule: leveraging evidence to support policy for accelerated impact. Vaccine. 2018;36(32PartA):4800-5. https://doi.org/10.1016/j.vaccine.2018.02.004

  8. Hernández-Ávila M, Torres-Ibarra L, Stanley M, Salmerón J, Cruz-Valdez A, Muñoz N, et al. Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: an epidemiological surveillance mechanism for alternate vaccination schemes. Hum Vaccin Immunother. 2016;12(1):30-8. https://doi.org/10.1080/21645515.2015.1058458

  9. Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309(17):1793-802. https://doi.org/10.1001/jama.2013.1625

  10. Krajden M, Cook D, Yu A, Chow R, Mei W, McNeil S, et al. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. Clin Vaccine Immunol. 2011;18(3):418- 23. https://doi.org/10.1128/CVI.00489-10

  11. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed Luminex assay. Clin Diagno Lab Immunol. 2003;10(1):108-15. https://doi.org/10.1128/CDLI.10.1.108-115.2003

  12. Dias D, Van Doren J, Schlottmann S, Kelly S, Puchalski D, Ruiz W, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol. 2005;12(8):959-69. https://doi.org/10.1128/ CDLI.12.8.959-969.2005

  13. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118(5):2135-45. https://doi.org/10.1542/peds.2006-0461

  14. Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007;26(3):201-9. https://doi.org/10.1097/01.inf0000253970.29190.5a

  15. Salmerón J, Torres-Ibarra L, Bosch FX, Cuzick J, Lörincz A, Wheeler CM, et al. HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico. Salud Publica Mex. 2016;58(2):211-9. https://doi.org/10.21149/spm.v58i2.7790

  16. Torres-Ibarra L, Lazcano-Ponce E, Franco EL, Cuzick J, Hernández-Ávila M, Lorincz A, et al. Triage strategies in cervical cancer detection in Mexico: Methods of the FRIDA study. Salud Publica Mex. 2016;58(2):197-210. https://doi.org/10.21149/spm.v58i2.7789

  17. Gayet C, Gutiérrez JP. Sexual debut in Mexico: a comparison of household national surveys. Salud Publica Mex. 2014;56(6):638-47. https://doi. org/10.21149/spm.v56i6.7391

  18. Lazcano-Ponce E, Herrero R, Muñoz N, Cruz A, Shah KV, Alonso P, et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer. 2001;91(3):412-20. https://doi.org/10.1002/1097- 0215(20010201)91:3<412::AID-IJC1071>3.0.CO;2-M

  19. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711-23. https://doi.org/10.1056/ NEJMoa1405044

  20. Van Damme P, Meijer CJ, Kieninger D, Schuyleman A, Thomas S, Luxembourg A, et al. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine. 2016;34(35):4205-12. https://doi.org/ 10.1016/j.vaccine.2016.06.056

  21. Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 2016;137(3):e20151968. https://doi.org/10.1542/ peds.2015-1968

  22. Ali H, McManus H, O’Connor CC, Callander D, Kong M, Graham S, et al. Human papillomavirus vaccination and genital warts in young Indigenous Australians: National sentinel surveillance data. Med J Aust. 2017;206(5):204-9. https://doi.org/ 10.5694/mja16.00597

  23. Thorsteinsson K, Storgaard M, Katzenstein TL, Ladelund S, Rønsholt FF, Johansen IS, et al. Prevalence and distribution of cervical high-risk human papillomavirus and cytological abnormalities in women living with HIV in Denmark - the SHADE. BMC Cancer. 2016;16(1):866. https://doi. org/10.1186/s12885-016-2881-1

  24. Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world Experience. Clin Infect Dis. 2016;63(4):519-27. https://doi.org/10.1093/cid/ciw354

  25. Machalek DA, Chow EP, Garland SM, Wigan R, Cornall AM, Fairley CK, et al. Human papillomavirus prevalence in unvaccinated heterosexual men after a national female vaccination program. J Infect Dis. 2017;215(2):202- 8. https://doi.org/10.1093/infdis/jiw530

  26. Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. Infect Dis. 2013;208(3):385-93. https://doi.org/10.1093/infdis/jit192




2020     |     www.medigraphic.com